Abstract:Glucocerenrosidase1 (GBA1) mutations cause disruptions in endoplasmic reticulum (ER) and lysosome‐related proteostasis pathways in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons. Severe GBA1 mutations lead to increased ER stress (increased binding immunoglobulin protein (BiP) and protein disulfide isomerase (PDI) levels), total ubiquitination rates, and unfolded protein response (UPR). Defective chaperone‐mediated autophagy (decreased heat‐shock cognate protein 70 (HSC70) levels and decreased co‐localization of lysosomal‐associated membrane protein 2A (LAMP2A) and HSC70) is observed in iPSC‐derived dopaminergic neurons with mild homozygous GBA1 mutations. Decreased autophagosome formation (decreased microtubule‐associated protein light chain 3A (LC3) levels) is observed in iPSC‐derived dopaminergic neurons with homozygous N370S and D409H GBA1 mutations, while fusion defects (decreased lysosomal‐associated membrane protein 1 (LAMP1) and LC3 co‐localization) are observed in neurons with homozygous L444P GBA1 mutation. Severe GBA1 mutations trigger the accumulation of monomeric and oligomeric forms of α‐synuclein. GBA1 mutations increase the release of α‐synuclein from iPSC‐derived dopaminergic neurons. Glucocerebrosidase 1 (GBA1) mutations are the most important genetic risk factors for Parkinson's disease (PD). Clinically, mild (e.g., p.N370S) and severe (e.g., p.L444P and p.D409H) GBA1 mutations have different PD phenotypes, with differences in age at disease onset, progression, and the severity of motor and non‐motor symptoms. We hypothesize that GBA1 mutations cause the accumulation of α‐synuclein by affecting the cross‐talk between cellular protein degradation mechanisms, leading to neurodegeneration. Accordingly, we tested whether mild and severe GBA1 mutations differentially affect the degradation of α‐synuclein via the ubiquitin–proteasome system (UPS), chaperone‐mediated autophagy (CMA), and macroautophagy and differentially cause accumulation and/or release of α‐synuclein. Our results demonstrate that endoplasmic reticulum (ER) stress and total ubiquitination rates were significantly increased in cells with severe GBA1 mutations. CMA was found to be defective in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons with mild GBA1 mutations, but not in those with severe GBA1 mutations. When examining macroautophagy, we observed reduced formation of autophagosomes in cells with the N370S and D409H GBA1 mutations and impairments in autophagosome–lysosome fusion in cells with the L444P GBA1 mutation. Accordingly, severe GBA1 mutations were found to trigger the accumulation and release of oligomeric α‐synuclein in iPSC‐derived dopaminergic neurons, primarily as a result of increased ER stress and defective macroautophagy, while mild GBA1 mutations affected CMA, which is mainly responsible for the degradation of the monomeric form of α‐synuclein. Overall, our findings provide new insight into the molecular basis of the clinical variability in PD associated with different GBA1 mutations.

GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice

GBA1 mutations alter neuronal firing and structure, regulating VGLUT2 and CRYAB in dopamine neurons

iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis

Variant‐specific effects of GBA1 mutations on dopaminergic neuron proteostasis

Inhibition of microglial β-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications

Linking Gba1 E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration

Gba1 E326K renders motor and non-motor symptoms with pathologic α-syn, tau and glial activation

Glucocerebrosidase and its relevance to Parkinson disease

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

Investigating the Impact of the Parkinson's-Associated GBA1 E326K Mutation on β-Glucocerebrosidase Dimerization and Interactome Dynamics Through an In Silico Approach

Neuronal Accumulation Of Glucosylceramide In A Mouse Model Of Neuronopathic Gaucher Disease Leads To Neurodegeneration

Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism

Upregulation of NFE2L1 reduces ROS levels and α-synuclein aggregation caused by GBA1 knockdown

Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson′s disease and Dementia with Lewy bodies

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art

Impaired neuron differentiation in GBA-associated Parkinson’s disease is linked to cell cycle defects in organoids

Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease

The loss of function GBA1 c.231C > G mutation associated with Parkinson disease

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutation